Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.
Journal Article (Journal Article)
Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.
Full Text
Duke Authors
Cited Authors
- Jones, DI; McGee, CE; Sample, CJ; Sempowski, GD; Pickup, DJ; Staats, HF
Published Date
- July 2016
Published In
Volume / Issue
- 23 / 7
Start / End Page
- 648 - 651
PubMed ID
- 27146001
Pubmed Central ID
- PMC4933771
Electronic International Standard Serial Number (EISSN)
- 1556-679X
Digital Object Identifier (DOI)
- 10.1128/CVI.00216-16
Language
- eng
Conference Location
- United States